drugset / Trial / NCT01631864

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

NCT01631864

Phase 2 Completed 98 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blind

Summary

This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.

Timeline

Start
2012-10
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg
Subject LCZ696 Unknown 400 mg

Indications